TrialCancer discovery2021

Tilsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma.

Cara Haymaker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.